BioSpace News Archive

Global Roundup: Affimed Cancer Asset Shows Early Promise

Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

November 24, 2021
·
4 min read
·
Alex Keown
Drug Development

Merck and Gilead Pause HIV Study out of “Abundance of Caution”

Both Gilead Sciences and Merck announced they were pausing a Phase II trial of islatravir and lenacapavir in HIV.

November 24, 2021
·
3 min read
·
Mark Terry
Business

Allorion Debuts with $40 Million to Enhance and Discover Precision Targets

The precision medicine company is developing mutant selective and isoform-specific drugs in non-conventional ways for well-known targets in the oncology and autoimmune spaces.

November 24, 2021
·
2 min read
·
Heather McKenzie
PreveCeutical Files Provisional Patent Application for D-Amino Acid Peptides

Compounds in these Peptides may be suitable for the treatment of cancers in which extracellular matrix metalloprotease (“MMP”) or other proteinases such as urokinase-type plasminogen activator (uPa) are implicated.

November 24, 2021
·
5 min read
FDA

FDA Greenlights First Treatment for Refractory Post-transplant CMV

The FDA approved Takeda’s Livtencity (maribavir) for adults and children 12 years or older with post-transplant cytomegalovirus (CMV) infection.

November 24, 2021
·
3 min read
·
Mark Terry
Genetown

Merck and Dragonfly, Together Again

Merck opted to license its second TriNKET immunotherapy candidate from Dragonfly Therapeutics. The option came one year after Merck licensed its first immunotherapy candidate.

November 24, 2021
·
2 min read
·
Alex Keown
Business

Money on the Move: November 17 – 23

Plenty to be thankful for this week for these biopharma companies, especially with the influx of cash.

November 24, 2021
·
3 min read
·
Kate Goodwin
Drug Development

Pfizer-licensed Cardiovascular Drug Reduces Triglycerides in Phase II

A cardiovascular drug Pfizer licensed from Akcea Therapeutics in 2019 hit the mark in a Phase IIb dose-ranging study in patients with elevated non-HDL-C and triglycerides.

November 24, 2021
·
2 min read
·
Alex Keown
Policy

COVID-19: Dire Predictions from WHO and Good News for Older Patients

Although vaccines and effective therapeutics are powerful tools in preventing and treating COVID-19, we’re not done battling the disease just yet. For those stories and more, read on.

November 24, 2021
·
3 min read
·
Mark Terry
Drug Development

Bonus BioGroup’s MesenCure Shows Promise Against COVID-19 Pneumonia

Bonus BioGroup’s product is back in the news again as its cell therapy promises to treat late-stage COVID-19.

November 24, 2021
·
3 min read
·
Mark Terry